COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01606072
Recruitment Status : Completed
First Posted : May 25, 2012
Last Update Posted : August 28, 2015
Information provided by (Responsible Party):
Laboratorio Elea Phoenix S.A.

Brief Summary:
The propose for this study is to evaluate the safety and tolerability of desmopressin when administered perioperatively to patients with breast cancer undergoing surgery as first treatment, and select the optimum dose for the clinical development of the product.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Desmopressin Phase 2

Detailed Description:
Breast cancer is one of the most commonly diagnosed malignancies among women, and its mortality is related to the capacity of tumor cells to invade and produce metastases. It is postulated that tumor manipulation during surgery results in the release of tumor cells into circulation or the lymphatic system, and that these released cells survive due to aggregation among them or with platelets through the formation of a fibrin layer on the embolus. Tumor cells surviving transportation through circulation will join blood vessels and invade vascular walls, forming metastases. The interruption of this process might reduce survival of tumor cells and thus the formation of metastases from breast cancer cells in the lungs or other tissues.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study
Study Start Date : November 2011
Actual Primary Completion Date : February 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Desmopressin Drug: Desmopressin
20 patients in 5 groups 4 each, advancing progressively to each dose level.

Primary Outcome Measures :
  1. Selection of the higher safe dose level for ensuing clinical trials [ Time Frame: Up to 2 years ]
    One of the three dose levels assessed in this study will be selected for further clinical testing in adults: 0,50 mg, 1,0 mg, 1,25 mg, 1,5 mg or 2,0 mg.

Secondary Outcome Measures :
  1. Evidence of V2 Receptor Expression [ Time Frame: Baseline ]
  2. Evidence of CTC (CIRCULATING TUMOR CELLS) [ Time Frame: Baseline ]
  3. Evidence of Von Willebrand factor antigen (VWF:Ag) [ Time Frame: Baseline ]
  4. Evidence of CTC (circulating tumor cells) [ Time Frame: 30 minutes pre surgery and 24 hours post the surgery ]
  5. Evidence of CTC (circulating tumor cells) [ Time Frame: 2 Weeks ]
  6. Evidence of CTC (circulating tumor cells) [ Time Frame: 1 Month ]
  7. Evidence of CTC (circulating tumor cells) [ Time Frame: 3 Months ]
  8. Evidence of CTC (circulating tumor cells) [ Time Frame: 6 Months ]
  9. Evidence of CTC (circulating tumor cells) [ Time Frame: 12 Months ]
  10. Evidence of Von Willebrand factor antigen (VWF:Ag) [ Time Frame: 120 minutes post the surgery ]
  11. Evidence of VWF activity (ristocetin cofactor, VWF:RCo) [ Time Frame: baseline ]
  12. Evidence of VWF activity (ristocetin cofactor, VWF:RCo) [ Time Frame: 120 minutes post the surgery ]
  13. Evidence of FVIII coagulant activity (FVIII:C) [ Time Frame: baseline ]
  14. Evidence of FVIII coagulant activity (FVIII:C) [ Time Frame: 120 minutes post the surgery ]
  15. Evidence of euglobulin lysis time [ Time Frame: baseline ]
  16. Evidence of euglobulin lysis time [ Time Frame: 120 minutes post the surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • a. Female subjects from 21 to 60 years of age, who have voluntarily signed the informed consent form.

    b. Histological/cytological diagnosis of breast carcinoma obtained at least 21 days before inclusion into the study.

    c. Candidate for radical mastectomy and requiring resection of axillary lymph nodes or sentinel node.

    d. In case of women of childbearing potential, an adequate birth control method (intrauterine device, barrier methods, or tubal ligation) should be used throughout the study. Post-menopausal women should have menopause confirmed by biochemical parameters.

    e. Adequate organic function, defined by the following parameters:

    • Electrocardiogram (ECG) with no significant anomalies, performed within 14 days prior to surgery.
    • The following laboratory results, obtained 7 days before surgery:
    • Hemoglobin ≥ 11 g/dL
    • Total white blood cell count ≥ 4,000/mm3
    • Total neutrophil count 1,500/mm3
    • Platelet count within normal limits
    • Total bilirubin ≤1.5 x UNL or 2.5 x UNL in case of hepatic metastasis
    • Transaminases ALT/GPT and AST/GOT ≤ 1.5 x UNL
    • Creatinine clearance >50 mg/dL
    • CT scan with oral and endovenous contrast* of chest, pelvis, and abdomen, and bone scan, conducted within 28 days prior to surgery. Images taken not longer than 90 days before surgery are also acceptable.

      • In case contrast is contraindicated, CT with no contrast or MRI will be performed.

        f. Subject with performance status (ECOG) = 0.

Exclusion Criteria:

  • a. Synchronic bilateral breast cancer. b. Symptoms of metastasis or evidence of metastasis from images: chest spiral CT scan, abdomen/pelvis spiral CT scan, brain spiral CT/MRI (in case of brain metastasis signs), and bone scan.

    c. The patient is pregnant or breastfeeding. d. The patient is presently using hormonal contraceptives or under hormonal treatment. She would be eligible if oral contraceptives were discontinued or if the hormonal treatment finished 30 days before surgery and the patient agreed to use another contraceptive method.

    e. Patients with a history or presence of congestive heart failure, blood hypertension, angina pectoris or heart arrhythmia, thromboembolic disease, diabetes type I or II, or any underlying coronaropathy detected in pre-surgical evaluations.

    f. Mentally-impaired patients. g. Patients with known hypersensitivity to DDAVP or vasopressin, o with severe von Willebrand's disease (VWD), defined by a VWF activity <10%IU/dL, or type 2B VWD, defined by an increased ristocetin-induced platelet aggregation (RIPA) at low concentrations of ristocetin or with hemophilia.

    h. Patients with a history of seizures. i. Patients with renal impairment (creatinine clearance < 50 mL/min calculated by the Cockcroft-Gault formula), hyponatremia or with a history of hyponatremia.

    j. Patients with syndrome of inadequate secretion of antidiuretic hormone. k. Patients with positive serology for the hepatitis B or C virus and/or HIV. l. Patients with known hepatic disease (diagnosed cirrhosis, hepatic enzymes (GOT/GPT) > 1.5 x UNL, Total bilirubin > 1.5 x UNL).

    m. Patients with active infections. n. Patients with other malignant diseases, with the exception of, non-melanoma skin cancer, or cervix cancer in situ, or any other tumor that has received adequate treatment and shows a disease-free time ≥ 5 years.

    o. Patients participating in another clinical study or cases in which less than 4 weeks have elapsed since participation in another clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01606072

Layout table for location information
Hospital Interzonal General De Agudos EvaPeron
Buenos Aires, Argentina
Sponsors and Collaborators
Laboratorio Elea Phoenix S.A.
Layout table for investigator information
Principal Investigator: Dra. Ruth Weinberg Hospital Interzonal General De Agudos Eva Peron
Publications of Results:
Layout table for additonal information
Responsible Party: Laboratorio Elea Phoenix S.A. Identifier: NCT01606072    
Other Study ID Numbers: DDAVP
First Posted: May 25, 2012    Key Record Dates
Last Update Posted: August 28, 2015
Last Verified: August 2015
Keywords provided by Laboratorio Elea Phoenix S.A.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Deamino Arginine Vasopressin
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs